Nerva Didn’t Work: 7 Reasons Why, and What to Try Next

This is a diagnostic guide, not a sales pitch. The goal is to help you figure out which of the seven common reasons is driving your non-response, because the right next step is different for each one — and for some profiles, a repeat self-directed attempt is still the correct move.

A note before the diagnostic list below. The experience of downloading a well-marketed IBS app, committing to six weeks of daily audio sessions, and finishing with no meaningful symptom change is disheartening. Many people who arrive at a clinician’s office after a self-directed attempt carry an internalised story that “hypnotherapy doesn’t work for me,” or worse, that their IBS is somehow resistant to treatment in a way other people’s isn’t. Both of those interpretations are usually wrong, and they close off options that are still very much on the table.

The manufacturer’s own data tells a more useful story. Peters SL, Gibson PR, Halmos EP. Neurogastroenterology & Motility. 2023;35(4):e14533. PMID 36661117. DOI 10.1111/nmo.14533 — this is the retrospective evaluation of Nerva’s own user base. It found that 2,843 people started the free trial, 1,428 (50%) purchased, 253 (9%) completed all 42 sessions, and outcome data was captured for 190 people — 6.7% of starters. Of those 190 completers, 64% reported significant improvement. The authors, who disclose financial ties to Mindset Health, concluded in writing that “adherence to app-delivered gut-directed hypnotherapy was low” and called for a controlled trial comparing face-to-face to app-delivered GDH — a trial that still doesn’t exist.

What that means in practice: if you didn’t respond to Nerva, you’re in the 91% of paying users for whom the app did not deliver a measurable result. That’s the modal outcome, not an edge case. The separate question of whether gut-directed hypnotherapy as a modality doesn’t work for you is a different question, and the evidence on clinician-delivered GDH — Miller 2015 (PMID 25736234) showing a 76% response rate in 1,000 consecutive refractory patients on the Manchester Protocol — looks very different from the app adherence numbers. One does not disprove the other. Your non-response to Nerva does not tell you much about how you’d respond to a live, adaptive, clinician-delivered protocol.

The seven reasons below are the diagnostic categories that account for most Nerva-didn’t-work stories. They are not mutually exclusive — it’s common for two or three to apply simultaneously. After the list there’s a decision-tree section that helps you figure out which one (or combination) is doing the most work in your specific case, and what the evidence-based next step is for each.

One framing note before the list. The page below is written for people who genuinely gave Nerva an honest try and didn’t get a response. It’s not written to argue that Nerva is a bad product or that everyone who tries it is making a mistake — for a specific user profile the app is a reasonable first move and does what it’s designed to do. The page is specifically for the larger group on the other side of that filter: the people for whom self-directed audio didn’t deliver, and who now need a clearer map of where to go next without cycling through another round of the same delivery format and hoping for a different result.

Seven diagnostic categories cover most Nerva non-response stories. The figure below maps them at a glance; each is explored in depth afterward. Reasons 1 through 4 are the most common; Reasons 5 through 7 tend to apply to more complex or atypical presentations.

This is the single largest category. Peters 2023 (PMID 36661117) found that 9% of paying users completed all 42 sessions, which means 91% did not. Simicich 2024 (PMC11179457), an independent evaluation, found that paid users averaged 18.22 of 42 sessions completed (about 43%), and that 31.7% of paid users even reached an end-of-program survey. The protocol was designed around daily listening, and the hypnotic mechanism depends on cumulative exposure to induction, deepening, and visceral-specific suggestion. Before session 15 or so, most patients in the Manchester Protocol clinical data have not yet shown measurable change either — that’s simply how the modality paces.

If you’re reading this and thinking “I did about three weeks and then life got in the way,” the honest clinical read is that the protocol hadn’t been delivered enough to be tested. You can’t conclude that gut-directed hypnotherapy doesn’t work for you from a partial dose, any more than you could conclude an antibiotic doesn’t work after finishing one third of the course. Research suggests symptom movement typically emerges between weeks 3 and 6 in clinician-delivered protocols, and the app protocol is a rough match for that curve. Stopping at week 2 or 3 puts you before the window where change is expected.

The adherence problem is also informative in a different direction. Daily self-directed audio work is genuinely hard to sustain alone, and most people don’t. The Manchester Protocol in its clinician-delivered form uses 7–12 sessions with a live practitioner, explicitly because the in-person structure provides accountability, personalized induction, and troubleshooting when a session falls flat. None of that is available in the app format. If adherence is the primary reason you stopped, the clinical pattern is that it rarely resolves on a second self-directed attempt — the same adherence barrier tends to reappear. A clinician-led course with scheduled sessions is the format that addresses adherence directly, because you have a standing appointment to show up to.

If this is you: you haven’t actually tested whether GDH works for your nervous system yet. The correct next step is either a structured re-attempt with realistic scheduling and a commitment to reach at least session 25 before drawing any conclusion, or — more commonly the faster path — a short clinician-led course where adherence is solved by the appointment structure itself.

A practical note on how to tell the difference between an adherence profile and a genuine non-response profile: keep a simple log of the sessions you complete and what you notice in each. If across 15 sessions you can point to any of the following — slower breathing that emerged spontaneously, a shift in body-temperature perception, time distortion (“that felt like five minutes” when it was fifteen, or vice versa), unusual dream activity in the nights following sessions, or transient GI calm in the hour after listening — hypnotic responsiveness is clearly present and the mechanism is engaging. Stopping at that point for scheduling reasons is a pure adherence issue, and the signal is that the protocol would likely continue to work if volume were sustained. If across 15 attentive sessions you can’t identify any of those shifts, the situation is different and the diagnostic question moves to Reasons 3 and 4.

IBS is a diagnosis of exclusion, which in practice means a meaningful subset of people walking around with an IBS label actually have a different condition that mimics the symptom pattern. Gut-directed hypnotherapy targets visceral hypersensitivity and brain-gut axis dysregulation — mechanisms that are central to genuine IBS but peripheral or irrelevant in other conditions that look similar on the surface. Self-directed hypnotherapy won’t help a structural, infectious, autoimmune, or endocrine condition, no matter how many sessions you complete.

The conditions most commonly misdiagnosed as IBS include:

• Small intestinal bacterial overgrowth (SIBO). Methane- or hydrogen-dominant overgrowth produces bloating, altered bowel habits, and post-prandial distress that look indistinguishable from IBS. Breath testing is the usual diagnostic step. GDH does not eradicate SIBO.
• Bile-acid malabsorption (BAM). Excess bile acids in the colon produce IBS-D-pattern diarrhea that often responds dramatically to a bile-acid sequestrant. BAM is underdiagnosed; some sources estimate it accounts for a meaningful fraction of patients labelled IBS-D. A gastroenterologist can test for it.
• Celiac disease. Celiac can present with IBS-like symptoms and is diagnosed via serology and duodenal biopsy, not clinical presentation. It requires a strict gluten-free diet, not hypnotherapy.
• Pelvic floor dysfunction. Incoordinated or hypertonic pelvic floor muscles produce constipation, incomplete evacuation, bloating, and pain patterns that get coded as IBS-C. A pelvic floor physiotherapist and anorectal manometry are the diagnostic path. GDH may help the anxiety component but won’t correct the mechanical issue.
• Carbohydrate malabsorption. Lactose, fructose, or sorbitol malabsorption produces FODMAP-pattern bloating and looseness that responds to dietary adjustment, not hypnotic reframing.
• Endometriosis (in women). Bowel-involved endometriosis presents with cyclic abdominal pain, altered bowel habits, and dyspareunia, and is frequently misdiagnosed as IBS for years. Imaging and specialist gynecology referral are the path.
• Microscopic colitis. Chronic watery diarrhea with normal colonoscopy appearance but abnormal biopsy. It’s missed when biopsies aren’t taken. Treatment is budesonide, not hypnotherapy.

A useful test for whether this reason applies to you is to retrace how the IBS label was applied. If your diagnosis came from a primary-care visit with no breath testing, no celiac serology, no pelvic floor assessment, no imaging, and no biopsies, the label is provisional rather than confirmed. That’s not a criticism of your physician — it’s an appropriate initial approach when symptoms are mild and there are no red flags — but it does mean the underlying pattern may not have been characterised.

If this is you: a gastroenterology work-up is the correct next step, not a repeat hypnotherapy attempt. Rule out structural and infectious drivers first. If the work-up confirms functional IBS, then gut-directed hypnotherapy becomes a targeted treatment again. If it identifies something else, the treatment pivots entirely.

A specific symptom pattern that should trigger this diagnostic pivot urgently: weight loss you didn’t intend, blood in stool, nocturnal diarrhea that wakes you, new-onset anaemia, persistent severe abdominal pain, fevers, or a family history of inflammatory bowel disease or colorectal cancer. These are red-flag features that warrant physician attention regardless of any hypnotherapy considerations, and a self-directed IBS app is categorically not the right tool if any of them are present. Most IBS presentations don’t involve red flags, but when they do, the treatment sequence is gastroenterology first, everything else later.

Hypnotic responsiveness is a stable individual trait with a recognisable distribution across the population. The research literature, drawing from scales like the Stanford Hypnotic Susceptibility Scale and the Harvard Group Scale, generally describes roughly 10–15% of adults as having low hypnotic responsiveness, about 70% as medium, and 15–20% as highly hypnotisable. The depth and quality of hypnotic experience varies meaningfully across this range. Pre-recorded audio protocols like Nerva are calibrated to a medium-hypnotisable profile; if you’re on the low end, the induction may feel inert or superficial, and the clinical depth required for gut-directed suggestion may not be reached.

A clinician can adapt to this. If a standard induction falls flat, a trained hypnotherapist has a toolkit of alternative induction styles (indirect, conversational, Ericksonian, somatic, hypnotic modalities that don’t rely on verbal depth at all) that can produce clinical effect in a low-hypnotisable client. That adaptive work is by definition unavailable in an app format — pre-recorded audio has one induction, one pace, and no feedback loop.

The signals that you might be in the low-hypnotizability range include: guided meditations, yoga nidra, and relaxation audios have never produced meaningful shifts for you even when you’ve tried; you find it hard to visualise imagery and generally experience internal states verbally rather than sensorially; and during the Nerva sessions you were aware of the recording the entire time without any shift in body perception, time perception, or ambient awareness. None of these are deficits — they’re cognitive-style variables. But they do mean self-directed audio is the least likely delivery format to work for you.

If this is you: a brief in-session hypnotic-depth assessment with a clinician can tell you where you sit on the responsiveness distribution, and whether an adapted induction style produces clinical depth. If it does, clinician-delivered GDH is a reasonable route. If it doesn’t, other modalities (CBT-for-IBS, medication, dietary approaches) are the better match and you haven’t wasted further time on a mismatched delivery format.

One caveat worth stating: hypnotic responsiveness is a trait, not a deficit, and being on the low end of the distribution is not a moral or cognitive failing. It tends to correlate with a particular cognitive style — strongly analytical, verbally dominant, low tolerance for ambiguous internal states — that’s protective and useful in most domains of life. Hypnosis happens to be the one place where the opposite cognitive style (associative, imaginative, comfortable with non-linear internal experience) responds more readily. Many low-hypnotisable people do exceptionally well with CBT-for-IBS or somatic therapies that don’t require the same state-shift mechanism. The clinical job is matching the modality to the cognitive profile, not pushing everyone through hypnosis regardless of fit.

Roughly 40–60% of clinical IBS populations meet criteria for comorbid anxiety, and smaller but significant subsets carry panic disorder, PTSD, or early-life trauma histories. Gut-directed hypnotherapy works on gut-brain axis dysregulation, and when generalized anxiety or trauma is driving the nervous-system state, the gut-brain piece is downstream of a larger autonomic pattern that needs to be addressed in parallel or first. Nerva is a gut-specific protocol; it doesn’t have modules for anxiety, panic, or trauma integration, and by design it cannot respond in real time if relaxation exercises produce hypervigilance or abreaction in a traumatised nervous system.

The common pattern is: a patient with an anxiety-dominant gut-brain presentation tries Nerva, finds the daily relaxation sessions either flat or slightly activating, doesn’t notice symptom change, and concludes hypnotherapy doesn’t work for them. What actually happened is that the delivery format can’t address the anxiety layer, and the gut layer won’t move until the anxiety layer does. Clinician-led work can integrate anxiety protocols (cognitive restructuring, interoceptive exposure, trauma-informed hypnosis) alongside gut-directed suggestion, or sequence them so the anxiety work comes first.

Trauma history is a further flag. Relaxation-based protocols in a deeply traumatised nervous system can occasionally trigger dissociation, hypervigilance, or flashback-like material. A live clinician can recognise this in real time and either shift induction style, slow the pace, or hold space for processing. Recorded audio can’t. Trauma-informed hypnotherapy is a specific skill set and is the appropriate path when trauma is relevant to the presentation.

If this is you: gut-directed hypnotherapy is still likely to help eventually, but the sequencing matters. Either address the anxiety component first (through CBT, EMDR, somatic experiencing, or anxiety-specific hypnotherapy) and then return to the gut protocol, or work with a clinician who can integrate both tracks concurrently. Self-directed audio for either component is the delivery format least likely to hold what’s needed.

A few signs that anxiety is the upstream driver rather than a downstream consequence of your IBS: symptoms are worse on Sunday nights or before known stressors even when diet is identical; you notice the anticipatory anxiety about having symptoms is itself symptom-provoking; your gut settles dramatically on vacation or in low-responsibility contexts; you have a history of other anxiety-adjacent presentations (panic, health anxiety, social anxiety, insomnia linked to rumination). When several of these are present, the clinical pattern is that the anxiety layer is doing most of the work and the gut is the end-organ expression. Treating the gut alone, through any modality, leaves the upstream driver untouched and tends to produce partial or transient improvement at best.

Refractory IBS — severe, long-standing, treatment-failing presentations — is paradoxically both the strongest indication for gut-directed hypnotherapy and the weakest indication for self-directed app delivery. Miller 2015 (PMID 25736234) was specifically an audit of 1,000 consecutive refractory patients at the University Hospital of South Manchester, and it found a 76% response rate on the clinician-delivered Manchester Protocol with benefits persisting 5+ years. That’s the headline evidence for the modality. But the refractory profile is also the profile least likely to complete a 42-session daily self-directed audio course, because refractory patients are often dealing with deeper central sensitisation, longer symptom histories, more frustration with prior treatment failures, and more complex comorbid pictures.

The Manchester Protocol in its clinician-delivered form typically runs 7–12 sessions over 2–3 months, with personalized suggestion, live troubleshooting when a session plateau appears, and between-session accountability. Those elements are load-bearing for refractory cases. The 42-session app protocol is a volumetric attempt to approximate clinician exposure through repetition, but without the adaptive element. For mild presentations that can be good enough. For refractory presentations with deeper central sensitisation, the 9% Peters 2023 completion rate maps almost directly onto the subset of users for whom this approach was never going to work — and refractory patients are over-represented in that subset.

Clinical pattern signs that your presentation is refractory include: 5+ years of symptom history, multiple failed prior treatments (low-FODMAP done properly, one or more IBS-specific medications, probiotics, fibre modulation, prior therapy), daily or near-daily symptom burden, and significant quality-of-life impact. If two or more of these apply, the Peters 2023 data profile is probably speaking about a group you’re in.

If this is you: clinician-led GDH on the Manchester Protocol framework is the most evidence-backed next step. The Miller 2015 76% response figure is specifically in a refractory population, which means it’s the relevant base rate for your presentation — not the app numbers. The cost of a 6–12 session course is meaningfully higher than the Nerva subscription, but the cost-per-response math favors the clinician route in refractory cases by a wide margin.

Worth flagging for refractory patients specifically: the experience of arriving at yet another treatment after multiple prior failures often involves a degree of treatment fatigue that is itself a barrier. If each new modality feels like another likely disappointment, it’s harder to engage the way clinician-delivered GDH requires. This is worth naming upfront with a clinician at the start of a course, because the first two or three sessions are often as much about rebuilding the possibility of improvement as they are about the hypnotic work itself. Refractory-population response curves tend to look different from first-episode response curves: change emerges slightly later, often with more initial resistance, and then holds more durably once it does emerge.

Gut-directed hypnotherapy builds over 6–12 weeks. That’s an unusually slow treatment arc compared to other IBS interventions — a low-FODMAP elimination phase shows dietary response within 2–4 weeks, an antispasmodic or loperamide produces effect within hours to days, and rifaximin or linaclotide trials typically read out within 2–4 weeks. Against that backdrop, the hypnotic protocol’s delayed onset can feel like non-response when it’s actually just pacing. Patients who expected week 1 or 2 results often quit at week 3 or 4, which is precisely when measurable change tends to begin in clinical data.

This is a particular risk with app delivery because there’s no weekly clinician check-in to reset expectations when a plateau is actually on-track. In a clinician format, session 3 or 4 is usually the point where the therapist explicitly names “you may not notice much yet, and that’s expected — here’s what to watch for in weeks 4–6.” Without that calibration, the absence of rapid response reads as failure.

If you quit Nerva around day 10–15 because nothing was happening, the honest reading is that nothing was supposed to be happening yet by the protocol’s own design. Research suggests symptom improvement in clinician-delivered GDH typically emerges between sessions 3 and 6 (or, in a daily app format, roughly days 21–42), with continued consolidation afterwards. Day 10 is early.

If this is you: a re-attempt with corrected expectations is reasonable, especially if no other reasons on this list apply. Commit to reaching session 25–30 before drawing any conclusion about modality response. If daily adherence is itself the problem (Reason 1), a clinician-led course solves both problems at once — the appointment structure sustains adherence, and the clinician recalibrates expectations in real time.

IBS is heterogeneous. Different patients have different dominant drivers — visceral hypersensitivity, motility dysregulation, carbohydrate-specific reactivity, anxiety-mediated gut-brain signalling, post-infectious inflammation, or some combination. Gut-directed hypnotherapy is evidence-backed and broadly effective, but it’s not universally the correct tool. For some presentations, CBT-for-IBS is a better fit; for others, low-FODMAP guidance with a Monash-trained dietitian; for others, targeted pharmacotherapy; for still others, pelvic floor physiotherapy. “Hypnotherapy didn’t work” may simply mean “hypnotherapy wasn’t the right answer for your specific presentation.”

CBT-for-IBS has an evidence base comparable in strength to gut-directed hypnotherapy, but it works through a different mechanism: cognitive restructuring, behavioural exposure, and attentional retraining rather than visceral-sensitivity reframing via hypnosis. It’s often a better fit when anxiety, catastrophizing, or health-related hypervigilance is the dominant feature. Some patients who don’t respond to GDH respond well to CBT-for-IBS and vice versa, because the underlying mechanism they’re engaging is different.

The low-FODMAP diet has strong evidence for a specific patient profile — IBS with clear food-triggered pattern, ideally supervised through a proper elimination-reintroduction protocol by a Monash-trained dietitian. If your symptom diary shows tight coupling between specific meals and gut episodes, and gut-brain-axis relaxation hasn’t shifted that pattern, the dietary route may simply be the better-matched intervention for your presentation.

If this is you: the useful information from your Nerva attempt isn’t “hypnotherapy doesn’t work.” It’s “the gut-brain axis via hypnotic induction isn’t the dominant lever for my presentation.” That’s actionable information. CBT-for-IBS, dietitian-led FODMAP work, or a gastroenterology-led medication trial may be a more direct match for your specific pattern. A 15-minute consultation can help triage which.

One more wrinkle on modality fit: some patients present with mixed mechanisms where food-triggered, anxiety-mediated, and motility-dysregulated components are all contributing, with no single dominant lever. In those cases a sequenced approach often works better than single-modality attempts — run low-FODMAP with a dietitian for the dietary component, treat anxiety with CBT or targeted hypnotherapy, and address remaining visceral-sensitivity patterns with gut-directed work once the other layers have stabilised. An app-delivered single-modality protocol is structurally unable to sequence in this way, which partly explains why complex presentations often don’t respond to it and do respond to coordinated clinician care.

Most Nerva-didn’t-work stories involve two or three of the above running at once. The decision tree below is a rough first-pass sorter. Work through it in order — the earlier reasons are more common and more actionable, so ruling them in or out first tends to be the most efficient path.

The “right next move” is different depending on which reasons above applied to your Nerva attempt. The four evidence-based paths, in rough order of how commonly they’re the correct answer for a Nerva non-responder:

Re-attempting Nerva is a reasonable move in a narrow set of circumstances, and a poor move outside them. The honest framing:

A useful frame for anyone who didn’t respond to Nerva: gut-directed hypnotherapy has non-responders even when delivered optimally. Miller 2015 (PMID 25736234) reported 76% response on the clinician-delivered Manchester Protocol in 1,000 consecutive refractory patients, which means 24% of patients in the best available delivery format did not meet response criteria. That’s not a flaw unique to app delivery — it’s the ceiling of the modality itself.

About a quarter of eligible patients don’t respond to GDH regardless of how it’s delivered, and identifying that subset faster is part of why clinician-led care is valuable (a clinician can recognise non-response pattern within a few sessions and pivot, whereas an app runs the full 42 sessions before any pivot is considered).

The characteristics most associated with non-response in the clinical literature include: very severe somatisation patterns where gut symptoms are one part of a broader pattern of functional symptoms; unaddressed major psychiatric comorbidity (particularly untreated major depression or active substance-use issues); low hypnotic responsiveness as measured on formal susceptibility scales; and presentations where the dominant pathology is not actually functional (misdiagnosed IBS, per Reason 2). These overlap with several of the seven reasons above — which is why non-response to an app doesn’t cleanly predict non-response to a clinician, because the app format filters people out for reasons other than intrinsic non-response.

Hasan 2019 (PMID 30702396) offers another data point. Face-to-face clinician GDH produced 76% response, live telehealth GDH produced 65%, and the difference wasn’t statistically significant. The implication is that live clinician presence — not physical in-room attendance — is the load-bearing variable. That matters because it means a virtual clinician-led course is close to equivalent to in-person, which widens access and keeps costs reasonable for non-responders to app delivery who want to try the clinician format.

The honest takeaway: Nerva non-response tells you something about Nerva as a delivery format for your profile. It tells you much less about gut-directed hypnotherapy as a modality for your presentation. For most Nerva non-responders, the 24% clinical-GDH non-response rate is the relevant base rate — meaning roughly three out of four Nerva non-responders would be expected to respond to clinician-led GDH, assuming none of the other reasons (misdiagnosis, untreated comorbidity, wrong modality for the presentation) are the primary driver. Ruling those out first, then attempting a clinician-led course, is the evidence-based sequence.

A few things worth saying plainly before the FAQ.

• Hypnotherapy is complementary care, not a substitute for medical diagnosis or treatment. It is not a regulated health profession in Alberta. New or worsening GI symptoms — especially with red-flag features like unintentional weight loss, rectal bleeding, new anaemia, nocturnal symptoms, family history of inflammatory bowel disease or colorectal cancer, or onset after age 50 — warrant a physician referral first, not a hypnotherapy session.
• No claim that this practice “succeeds where Nerva fails.” The appropriate framing is that clinician-delivered GDH has a different evidence base with different adherence and response characteristics. The Miller 2015 76% response figure on the Manchester Protocol is the relevant clinician-delivered benchmark; the Nerva numbers are the relevant app-delivered benchmark. Those numbers are what they are — individual results vary.
• No affiliation with Mindset Health or any other digital therapeutics vendor. This page is written from a clinical practice perspective. The practice has a commercial interest in clients choosing clinician-led sessions; that interest is disclosed. It’s also the reason the page goes to some length to describe where Nerva genuinely is the right first move — an honest review should acknowledge that even when acknowledging it means the reviewer earns less.
• No fabricated testimonials. Nothing on this page is a client anecdote with an invented name. Clinical pattern descriptions are drawn from published research and standard clinical observation, not from specific clients.